Daily Stock Analysis, CCXI, ChemoCentryx Inc, priceseries

ChemoCentryx Inc. Daily Stock Analysis
Stock Information
Open
10.86
Close
10.86
High
11.01
Low
10.56
Previous Close
10.70
Daily Price Gain
0.16
YTD High
12.81
YTD High Date
Jan 18, 2019
YTD Low
10.56
YTD Low Date
Feb 14, 2019
YTD Price Change
-0.21
YTD Gain
-1.90%
52 Week High
15.08
52 Week High Date
Mar 21, 2018
52 Week Low
8.77
52 Week Low Date
Feb 20, 2018
52 Week Price Change
1.46
52 Week Gain
15.53%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 7. 2017
7.11
Jul 18. 2017
9.84
28 Trading Days
38.36%
Link
LONG
Jan 3. 2018
6.19
Feb 5. 2018
8.80
22 Trading Days
42.22%
Link
LONG
Mar 1. 2018
9.82
Mar 27. 2018
13.96
18 Trading Days
42.17%
Link
LONG
May 15. 2018
11.43
Jun 4. 2018
12.47
13 Trading Days
9.12%
Link
LONG
Aug 24. 2018
11.48
Sep 6. 2018
12.51
8 Trading Days
8.97%
Link
Company Information
Stock Symbol
CCXI
Exchange
NasdaqGS
Company URL
http://www.chemocentryx.com
Company Phone
650-210-2900
CEO
Thomas J. Schall
Headquarters
California
Business Address
850 MAUDE AVENUE, MOUNTAIN VIEW, CA 94043
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001340652
About

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company, which engages in commercialization and development of pharmaceutical products. It focuses on discovering, developing, and commercializing therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders, and cancer. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

Description

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan (CCX168), an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn's diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis. It has a partnership with Vifor (International) Ltd. for the geographic commercial rights of Avacopan in Europe and other international markets. ChemoCentryx, Inc. was founded in 1997 and is headquartered in Mountain View, California.